ĀÜĄņĀŅĀ×

Roni Mamluk is a Venture Advisor at Israel Biotech Fund. Roni is also the CEO at Ayala Pharmaceuticals. Roni is a senior biopharmaceutical executive with 14 years of experience in drug development companies and a background in all aspects of R&D, general management, and fundraising.

Prior to Ayala Roni was the CEO of Chiasma (NASDAQ: CHMA). She is an inventor of their oral delivery technology, led the development of their lead product through all stages of development, including NDA submission. She was a key player in fundraising for the company including several private financing rounds and led a $70 million crossover financing and a successful IPO of over $100 million in 2015. Roni is now a board member at Chiasma.

Prior to that, she was heading the preclinical development of an oncology product at Adnexus (later acquired by Bristol-Myers Squibb (NYSE: BMY)).

She completed her postdoc at Childrenā€™s Hospital/Harvard Medical School in the field of angiogenesis and received her Ph.D., summa cum laude, from the Hebrew University in Jerusalem.